



(12) **CORRECTED EUROPEAN PATENT SPECIFICATION**

(15) Correction information:
Corrected version no 1 (W1 B1)
Corrections, see
Bibliography INID code(s) 54

(48) Corrigendum issued on:
15.07.2020 Bulletin 2020/29

(45) Date of publication and mention
of the grant of the patent:
01.04.2020 Bulletin 2020/14

(21) Application number: **16755729.7**

(22) Date of filing: **26.02.2016**

(51) Int Cl.:
A61K 45/00 ^(2006.01) **A61K 31/4412** ^(2006.01)
A61K 31/4439 ^(2006.01) **A61K 31/444** ^(2006.01)
A61K 31/4453 ^(2006.01) **A61K 31/5377** ^(2006.01)
A61K 31/541 ^(2006.01) **A61K 31/55** ^(2006.01)
A61P 35/00 ^(2006.01) **A61P 35/04** ^(2006.01)
G01N 33/15 ^(2006.01) **G01N 33/50** ^(2006.01)

(86) International application number:
PCT/JP2016/055927

(87) International publication number:
WO 2016/136985 (01.09.2016 Gazette 2016/35)

(54) **PYRIDINONE COMPOUND AND USE THEREOF**

PYRIDINONVERBINDUNG UND VERWENDUNG DAVON

COMPOSÉ PYRIDINONE ET UTILISATION DE CE DERNIER

(84) Designated Contracting States:
AL AT BE BG CH CY CZ DE DK EE ES FI FR GB
GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO
PL PT RO RS SE SI SK SM TR

(30) Priority: **27.02.2015 JP 2015039071**

(43) Date of publication of application:
03.01.2018 Bulletin 2018/01

(60) Divisional application:
20162312.1

(73) Proprietor: **Kyushu University,**
National University Corporation
Fukuoka-shi
Fukuoka 812-8581 (JP)

(72) Inventors:
• **FUKUI, Yoshinori**
Fukuoka-shi
Fukuoka 812-8581 (JP)
• **URUNO, Takehito**
Fukuoka-shi
Fukuoka 812-8581 (JP)
• **KANAI, Motomu**
Tokyo 113-8654 (JP)

- **MATSUNAGA, Shigeki**
Tokyo 113-8654 (JP)
- **SHIRAI, Takahiro**
Tokyo 113-8654 (JP)
- **YOKOYAMA, Shigeyuki**
Yokohama-shi
Kanagawa 230-0045 (JP)
- **HONMA, Teruki**
Yokohama-shi
Kanagawa 230-0045 (JP)
- **NIINO, Mutsuko**
Yokohama-shi
Kanagawa 230-0045 (JP)
- **TAKAYA, Daisuke**
Yokohama-shi
Kanagawa 230-0045 (JP)

(74) Representative: **Vossius & Partner**
Patentanwälte Rechtsanwälte mbB
Siebertstrasse 3
81675 München (DE)

(56) References cited:
WO-A1-2006/024823 WO-A1-2012/157389
WO-A2-2008/079787 CA-A1- 2 726 588
JP-A- 2011 522 056

Note: Within nine months of the publication of the mention of the grant of the European patent in the European Patent Bulletin, any person may give notice to the European Patent Office of opposition to that patent, in accordance with the Implementing Regulations. Notice of opposition shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).

- CARDAMA ET AL.: "Preclinical Development of Novel Rac1-GEF Signaling Inhibitors using a Rational Design Approach in Highly Aggressive Breast Cancer Cell Lines", ANTI-CANCER AGENTS IN MEDICINAL CHEMISTRY, vol. 14, 1875-599, 1 January 2014 (2014-01-01), pages 840-855, XP55551163,
- AKIHIKO NISHIKIMI ET AL: "Blockade of Inflammatory Responses by a Small-Molecule Inhibitor of the Rac Activator DOCK2", CHEMISTRY AND BIOLOGY., vol. 19, no. 4, 1 April 2012 (2012-04-01), pages 488-497, XP055551155, GB ISSN: 1074-5521, DOI: 10.1016/j.chembiol.2012.03.008
- BOUQUIER N ET AL: "A Cell Active Chemical GEF Inhibitor Selectively Targets the Trio/RhoG/Rac1 Signaling Pathway", CHEMISTRY AND BIOLOGY, CURRENT BIOLOGY, LONDON, GB, vol. 16, no. 6, 26 June 2009 (2009-06-26), pages 657-666, XP026211470, ISSN: 1074-5521, DOI: 10.1016/J.CHEMBIOL.2009.04.012 [retrieved on 2009-06-25]
- FENG, H. ET AL.: 'Phosphorylation of dedicator of cytokinesis 1 (Dock180) at tyrosine residue Y722 by Src family kinases mediates EGFRvIII-driven glioblastoma tumorigenesis' PNAS vol. 109, no. 8, 2012, pages 3018 - 3023, XP055478393
- JARZYNKA, M. J. ET AL.: 'ELMO1 and Dock180, a Bipartite Rac1 Guanine Nucleotide Exchange Factor, Promote Human Glioma Cell Invasion' CANCER RES. vol. 67, no. 15, 2007, pages 7203 - 7211, XP055478404
- LAURIN, M. ET AL.: 'Rac-specific guanine nucleotide exchange factor DOCK1 is a critical regulator of HER2-mediated breast cancer metastasis' PNAS vol. 110, no. 18, 2013, pages 7434 - 7439, XP055478420
- SANEMATSU, F. ET AL.: 'Phosphatidic Acid-dependent Recruitment and Function of the Rac Activator DOCK1 during Dorsal Ruffle Formation' JBC vol. 288, no. 12, 2013, pages 8092 - 8100, XP055478423
- OWA, T. ET AL.: 'Synthesis and Biological Evaluation of N-(7-Indolyl)-3-pyridinesulfonamide Derivatives as Potent Antitumor Agents' BIOORGANIC & MEDICINAL CHEMISTRY LETTERS vol. 12, 2002, pages 2097 - 2100, XP002980660